Zealand Pharma A/S (OCSE:ZEAL) EV-to-Revenue : 109.30 (As of Apr. 25, 2024)

View and export this data going back to 2010. Start your Free Trial

What is Zealand Pharma A/S EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Zealand Pharma A/S's enterprise value is kr37,467.5 Mil. Zealand Pharma A/S's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was kr342.8 Mil. Therefore, Zealand Pharma A/S's EV-to-Revenue for today is 109.30.

The historical rank and industry rank for Zealand Pharma A/S's EV-to-Revenue or its related term are showing as below:

OCSE:ZEAL' s EV-to-Revenue Range Over the Past 10 Years
Min: -5292.45 Med: 34.86 Max: 9643.61
Current: 109.3

During the past 13 years, the highest EV-to-Revenue of Zealand Pharma A/S was 9643.61. The lowest was -5292.45. And the median was 34.86.

OCSE:ZEAL's EV-to-Revenue is ranked worse than
85.09% of 1033 companies
in the Biotechnology industry
Industry Median: 7.63 vs OCSE:ZEAL: 109.30

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-04-25), Zealand Pharma A/S's stock price is kr626.00. Zealand Pharma A/S's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was kr5.74. Therefore, Zealand Pharma A/S's PS Ratio for today is 108.98.

Zealand Pharma A/S EV-to-Revenue Historical Data

The historical data trend for Zealand Pharma A/S's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zealand Pharma A/S EV-to-Revenue Chart

Zealand Pharma A/S Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EV-to-Revenue

Get a 7-Day Free Trial

175.13

39.86

51.87

92.63

59.14

Zealand Pharma A/S Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EV-to-Revenue	Get a 7-Day Free Trial															92.63	99.68	138.27	47.64	59.14

Competitive Comparison of Zealand Pharma A/S's EV-to-Revenue

For the Biotechnology subindustry, Zealand Pharma A/S's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Zealand Pharma A/S's EV-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Zealand Pharma A/S's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Zealand Pharma A/S's EV-to-Revenue falls into.

Zealand Pharma A/S EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Zealand Pharma A/S's EV-to-Revenue for today is calculated as:

EV-to-Revenue	=	Enterprise Value (Today)	/	Revenue (TTM)
	=	37467.462	/	342.787
	=	109.30

Zealand Pharma A/S's current Enterprise Value is kr37,467.5 Mil.
Zealand Pharma A/S's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was kr342.8 Mil.

Zealand Pharma A/S (OCSE:ZEAL) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Zealand Pharma A/S's PS Ratiofor today is calculated as:

PS Ratio	=	Share Price (Today)	/	Revenue per Share (TTM)
	=	626.00	/	5.744
	=	108.98

Zealand Pharma A/S's share price for today is kr626.00.
Zealand Pharma A/S's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was kr5.74.

Zealand Pharma A/S EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Zealand Pharma A/S's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Zealand Pharma A/S (OCSE:ZEAL) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zealand Pharma A/S (OCSE:ZEAL) » Definitions » EV-to-Revenue

Comparable Companies

Traded in Other Exchanges

ZLDPF:USA ZEALc:UK 0NZU:UK 22Z:Germany

Address

Sydmarken 11, Soborg, DNK, DK-2860

Website

https://www.zealandpharma.com

Zealand Pharma A/S is a biotechnology company. It is focused on the discovery, design, and development of peptide-based medicines. The company's product pipeline includes three product candidates in clinical development: glepaglutide, which is being developed to treat short bowel syndrome or SBS; dasiglucagon formulated for use in a dual-hormone artificial pancreas system for diabetes management; and dasiglucagon for use in the treatment of congenital hyperinsulinism. The company has out-licensed a peptide program to Boehringer Ingelheim that has been moved ahead into early clinical development: a once-weekly novel dual-acting GLP-1/glucagon agonist for the treatment of obesity and/or Type 2 diabetes.